A trial fibrillation (AF) is associated with the development of left atrial (LA) and LA appendageal thrombi, which are the main source of stroke and systemic embolism (1) . Transesophageal echocardiograms (TEEs) are recognized as the gold standard for evaluating for the presence of LA thrombus and is routinely used before cardioversion and catheter ablation procedures to minimize the risk of periprocedural stroke (2) . Risk factors such as structural heart disease, LA enlargement, and increased CHADS 2 scores have been identified as predictors of LA thrombus detection by TEE in patients undergoing pulmonary vein isolation (3-6).
Despite $3 to 4 weeks of continuous warfarin therapy, the rates of LA thrombus detection before cardioversion or catheter ablation have been shown to be substantial, with ranges reported between 1.6% and 7.7% (4, 6, 7) . TEE IMAGING. TEEs were performed in all study patients within 3 days of planned catheter ablation.
Imaging was performed using a General Electric Vivid 4 system (General Electric, Milwaukee, Wisconsin). 
Frenkel et al. Table 4 Percentages of patients with transesophageal echocardiography findings are displayed.
Abbreviations as in Figure 1 . 
Frenkel et al. to 82% (7, 24) . We identified an overall 64% rate of LA thrombus resolution after initial TEE with modification of the oral anticoagulation regimen. Given the limited number of patients with LA thrombus and the heterogeneity in the follow-up regimen of these patients, we were unable to make conclusions about the optimal anticoagulation strategy for LA thrombus resolution. Moreover, the time course of LA thrombus resolution is an important factor to consider. In our study, only 5 of the 9 patients who had eventual LA thrombus resolution were thrombus-free at first
repeat TEE performed at a median of 2.1 months after initial TEE. Three patients were found to have LA thrombus resolution only after repeated TEEs were performed >5 months after initial study.
STUDY LIMITATIONS. Our study has several limitations, including its retrospective design. Second, among NOAC patients, the use of dabigatran, rivaroxaban, and apixaban was not evenly distributed.
The low number of patients on apixaban reflects the later introduction of this drug into clinical use compared with the other NOAC agents during our study period. Therefore, our study was underpow- 
